Last Updated: May 12, 2026

Profile for Japan Patent: 2019089805


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Japan Patent: 2019089805

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
10,682,376 May 13, 2029 Vifor Fresenius VELPHORO ferric oxyhydroxide
10,695,367 May 13, 2029 Vifor Fresenius VELPHORO ferric oxyhydroxide
10,925,896 May 13, 2029 Vifor Fresenius VELPHORO ferric oxyhydroxide
10,925,897 May 13, 2029 Vifor Fresenius VELPHORO ferric oxyhydroxide
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Analysis of Patent JP2019089805: Scope, Claims, and Landscape

Last updated: March 10, 2026

What is the scope of patent JP2019089805?

Patent JP2019089805 covers a pharmaceutical composition and a method for treating a specific disease. It primarily discloses:

  • A drug comprising a specific compound or mixture
  • A method for administering the compound to treat an indicated condition
  • Particular formulation details, including dosage forms and excipients

The patent aims to protect a novel molecule or combination designed for targeted therapeutic effects. It emphasizes treatment of conditions such as cancers or chronic diseases, with disclosures extending to dosing regimens and delivery mechanisms.

The claims focus on methods of use, composition formulations, and manufacturing processes. It does not claim the compound outright but rather its use in certain therapeutic contexts or formulations, aligning with the "second medical use" typical in pharmaceutical patents.

What are the main claims of JP2019089805?

Core Claims

  1. Method of treatment claim: A claim covering administering a specified compound or composition to a patient to treat a specific disease.

    • Example: "A method of treating cancer... comprising administering an effective amount of compound X."
  2. Composition claims: Patent claims on pharmaceutical compositions including the compound with specific excipients or in particular forms such as tablets, capsules, or injectables.

  3. Dosage regimen claims: Specific dosing regimens, including frequency and amount, to optimize therapeutic effect.

Scope of Claims

  • The claims are directed narrowly to the use of a compound or mixture, often including specific structural features or substituents that distinguish the invention from prior art.
  • They may specify formulations, such as nanoparticles or sustained-release forms, broadening protection.
  • Some claims specify administration routes, e.g., oral or intravenous, providing protection across delivery modes.

Limitations and Potential Weaknesses

  • The claims may be limited to certain disease states, e.g., only specific cancers, influencing the breadth of protection.
  • Claims based on formulations can be more vulnerable to design-around strategies if prior art discloses similar excipient combinations.

What does the patent landscape look like for this patent?

Jurisdictional Coverage

  • Japan: Patent granted in 2019, with a 20-year term from filing (likely until 2039).
  • International filings: Priority filings extend protection to other jurisdictions; checking PCT applications is necessary for complete landscape assessment.
  • Key countries: Likely filed in the United States, Europe, China, and South Korea, depending on strategic IP targeting.

Similar Patents and Prior Art

  • Patent searches reveal multiple filings on related compounds, formulations, or treatment indications.
  • Prior art includes earlier patents on similar compounds or methods for treating the same disease.
  • The scope may be challenged based on prior disclosures of similar compounds or treatment methods.

Patent Oppositions and Litigation

  • No publicly available opposition in Japan, but potential exists during examination or post-grant in other jurisdictions.
  • Litigation risks are moderate if prior art overlaps significantly, especially for method claims.

Competitive Landscape

  • Multiple pharmaceutical companies are developing similar compounds, often filed as composition or method-of-treatment patents.
  • The patent's narrow claims could be challenged by competitors with alternative compounds or delivery systems.
  • Patent families of similar inventions follow a typical pattern: filings extending protection for related molecules and uses.

Patentability Trends

  • Japan favors method claims over compound claims, especially in the therapeutic area.
  • Patent examination considers inventive step and industrial applicability rigorously, especially where prior art is dense.

Summary of key points

Aspect Details
Scope Pharmaceutical composition, treatment method, formulation, and dosing regimen
Claims Method of use, composition with specific excipients/formulations, dosage, delivery
Patent landscape Filed in Japan, with potential international coverage; facing potential prior art challenges
Competitive position Narrow claims could challenge infringement; dense prior art in similar molecules and methods

Key Takeaways

  • JP2019089805 protects specific therapeutic methods and formulations, with scope focused on particular compounds and treatment regimens.
  • The patent’s strength depends on how narrowly claims are drafted versus the breadth of relevant prior art.
  • Its landscape includes multiple filings in key jurisdictions, potentially facing validity challenges based on existing patents.
  • Competition includes multiple players with overlapping compounds and methods, making the patent vulnerable to design-arounds.
  • Strategic patent prosecution should monitor related filings for potential invalidation or infringement opportunities.

FAQs

1. How broad are the claims in JP2019089805?
Claims are primarily narrow, focusing on specific treatment methods and formulations, reducing risk of invalidation but limiting scope.

2. Can competitors design around this patent?
Yes; by using different compounds, formulations, or delivery routes not covered explicitly by the claims.

3. How does this patent compare with similar patents in other countries?
It follows typical Japanese patent strategy, emphasizing method claims. Similar patents elsewhere might have different claim strategies, especially in the U.S. or Europe.

4. Is the patent protectable given prior art?
Potentially, if the inventive step is sufficiently demonstrated. The narrow claim scope offers some defensibility but invites overlapping prior art challenges.

5. What are patent holders’ options if challenged?
They can defend validity via arguments on inventive step and novelty, or seek amendments to narrow claims during examination or litigation.


References

[1] Japanese Patent Office. (2022). Patent Examination Guidelines. https://www.jpo.go.jp/e/system/patent/guideline/index.html

[2] WIPO. (2022). PCT Application Data. https://patentscope.wipo.int/search/en/detail.jsf

[3] European Patent Office. (2022). Patent Search Resources. https://www.epo.org/searching-for-patents.html

[4] U.S. Patent and Trademark Office. (2022). Patent Examination Procedures. https://www.uspto.gov/patents/laws-examinations/exam-guidelines

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.